Please assess the completion status of the following clinical trial:

Trial Title: Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~A patient must meet the following criteria to be eligible for inclusion in the study:~1. Candidates for corneal transplantation (only one eye per patient would be enrolled)~2. Patients with corneal neovascularization in one or more quadrants crossing more than 1.0 mm over the limbus at time of enrollment in the study~3. Willing and able to comply with clinic visits and study-related procedures~4. Provide signed informed consent~5. Age 18 or over~Exclusion Criteria:~A patient who meets any of the following criteria will be excluded from the study:~1. Patients receiving antiangiogenic anti-VEGF medication either systemically or intravitreally for other pathology or have received these drugs within 3 months of study enrollment~2. Patients with active corneal infection requiring additional treatment modalities~3. Patients receiving coumadin with INR \>2.0, other anti-thrombotic agents (e.g., aspirin, Plavix) permitted at discretion of investigator~4. History of cerebrovascular accident or myocardial infarction within 6 months prior to study enrollment~5. Uncontrolled blood pressure- defined as SBP\>160 mmHg or DBP \>95mmHg while patient is sitting~6. Pregnant or breast-feeding women~7. Sexually active men\* or women of childbearing potential\*\* who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device \[IUD\]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) \*Contraception is not required for men with documented vasectomy. \*\*Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A subconjunctival aflibercept (Type: EXPERIMENTAL): Patients will receive 2mg (0.05mL) subconjunctival aflibercept injection in addition to standard of care treatment (steroids and cyclosporine). Patients will receive one injection four weeks (+/- 1 week) prior to transplantation. They will receive a second injection at the conclusion of corneal transplantation.~Patients may receive as-needed repeat injections (minimum of 30 days in between treatments) for recurrence of corneal neovascularization (defined as \>1.0 mm crossing onto the cornea, past the limbus, or extension of vessels beyond previously documented extent) during the follow-up period.
- Group B: Standard of care only (Type: PLACEBO_COMPARATOR): Patients will receive standard of care (steroids and cyclosporine) treatment only.

Based on this trial design, predict the completion outcome and termination type (if applicable).